Mergers & Acquisitions - Biotechnology, Respiratory and Pulmonary

Filter

Popular Filters

Analysis of Roche’s InterMune acquisition

Analysis of Roche’s InterMune acquisition

28-08-2014

The acquisition of InterMune gives Swiss drug major Roche a substantial opportunity, owing to the Breakthrough…

BiotechnologyIdiopathic pulmonary fibrosisInterMuneMergers & AcquisitionspirfenidonePulmozymeRespiratory and PulmonaryRocheSwitzerlandXolair

Theravance to split into two, halting speculation of a full takeover by GSK

29-04-2013

US drug developer Theravance (Nasdaq: THRX) has announced its intention to create two independent publicly…

Anoro ElliptaBiotechnologyBreo ElliptaGlaxoSmithKlineManagementMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryRoyalty Management CoTheravanceTheravance Biopharma

Briefs: Sanofi to up stake in Regeneron; Bayer files for riociguat approval

12-02-2013

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares rise 4.8% to $173.84 in early trading…

BayerBiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegeneronRegulationRespiratory and PulmonaryriociguatSanofi

Fresenius Kabi sells respiratory homecare business in France

17-12-2012

Germany-based Fresenius Kabi, a provider of infusion therapy and clinical nutrition. has signed an agreement…

BiotechnologyFresenius BiotechFresenius KabiMergers & AcquisitionsPharmaceuticalRespiratory and Pulmonary

GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with Human Genome?

16-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) announced on Friday…

BiotechnologyBreoEuropeGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationRelovairRelvarRespiratory and PulmonaryTheravance

InterMune to divest Actimmune for $55 million; to focus on Esbriet

22-05-2012

California, USA-based biotech firm InterMune (Nasdaq: ITMN) says that it has reached a definitive agreement…

ActimmuneBiotechnologyEsbrietFinancialImmunologicalsInterMuneMergers & AcquisitionsRespiratory and PulmonaryVidara Therapeutics

Back to top